Physician profile
Jonathon Shaffer
NPI 1952367575
$1,927.49
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $249 · 2021: $262 · 2022: $315 · 2023: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $219.28 | 2019-2022 | |
| Novo Nordisk INC | $174.71 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $169.56 | 2021-2023 | Vraylar, Ubrelvy |
| Pfizer INC. | $148.12 | 2019-2023 | |
| Glaxosmithkline, LLC. | $147.80 | 2020-2023 | Fluarix Quadrivalent, Shingrix, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $121.48 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.64 | 2019-2023 | Jardiance |
| Amgen INC. | $84.52 | 2019-2023 | Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $83.41 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $70.27 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.70 | 2019 | |
| Amarin Pharma, INC. | $59.54 | 2019-2021 | |
| Allergan, INC. | $59.30 | 2020 | |
| Ironshore Pharmaceuticals INC. | $57.65 | 2019 | |
| Eisai INC. | $56.28 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $51.30 | 2019 | |
| Sanofi-Aventis U.S. LLC | $49.35 | 2019-2020 | |
| Sanofi Pasteur INC. | $45.64 | 2019-2023 | |
| Lilly USA, LLC | $37.32 | 2019-2023 | Emgality, Jardiance |
| Corium, LLC | $26.62 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $25.46 | 2019 | |
| Abbott Laboratories | $19.38 | 2021 | |
| Scilex Pharmaceuticals INC. | $14.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.86 | 2022 | |
| Ibsa Pharma INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.